Cannabinoid-phospholipid conjugates with cleavable linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid delivery methods lack efficient mechanisms for targeted and controlled release of cannabinoids within the body, particularly in a form that can be enzymatically activated for therapeutic efficacy.
Innovation Solution
Development of cannabinoid-phospholipid conjugates with a cleavable linker, where cannabinoids like CBD are covalently linked to phospholipids via a maleic acid linkage, allowing enzymatic release at specific sites within the body, utilizing a method involving reaction with maleic anhydride and carboxyl activating agents to form a stable conjugate that can be administered and released as needed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoids are administered directly, then they can reach the target site, but they lack controlled and targeted release mechanisms
Solution Approach 1:
The patent changes the chemical parameter of the cannabinoid by conjugating it to a phospholipid via a maleic acid linker. This modification transforms the free cannabinoid into a prodrug conjugate that can be incorporated into lipid structures, enabling controlled release through enzymatic cleavage of the linker at the target site.
Solution Approach 2:
The patent creates a composite structure by combining cannabinoid (A) with phospholipid (PL) through a cleavable linker. This composite conjugate can be integrated into lipid-based delivery vehicles such as liposomes or lipid nanoparticles, providing both structural integrity for delivery and enzymatically cleavable bonds for controlled release.
2Reliability
If cannabinoids are released continuously, then they maintain presence in the body, but they lack specificity of action and therapeutic efficacy
Solution Approach 1:
The patent introduces a dynamic release mechanism where the cannabinoid is initially held in a stable conjugate form and released only when enzymatic conditions at the target site cleave the maleic acid linker. This transforms the static delivery system into a dynamic one that responds to biological enzymes, providing specificity of action while maintaining appropriate duration of release.
3Stability of the object's composition
If a stable conjugate is formed, then the cannabinoid can be delivered effectively, but the release mechanism becomes less controllable
Solution Approach 1:
The patent introduces a maleic acid linker as an intermediary between the cannabinoid and phospholipid. This intermediary provides a stable conjugate structure for delivery while simultaneously incorporating an enzymatically cleavable bond that enables controlled release. The linker acts as a mediator that balances stability during delivery with controllability during release.
Data Source
AI summary
Provided is a cannabinoid-phospholipid conjugate where the cannabinoid is covalently linked, via a cleavable linker, to a polar head group of the phospholipid. Also provided is a method of obtaining the conjugate, the method comprising (a) reacting the phospholipid (PL) dissolved in an organic solvent with maleic anhydride (MA) to obtain PL-MA intermediate; and (b) reacting said PL-MA intermediate with the cannabinoid in the presence of a carboxyl activating agent and an esterification agent to obtain a reaction mixture comprising said conjugate. Uses of the conjugate are also disclosed.